Stockchase Opinions

Jim Cramer - Mad Money Humana Inc HUM-N BUY ON WEAKNESS Nov 08, 2023

The markets has this wrong. They reported last week then shares tumbled more than 6% in a strong market week. He's taken profits on this but still owns many shares. Is beating the S&P since June. HUM actually reported a good quarter: strong earnings beat, 6% up YOY, sales up 18%. But shares came up way too high leading up to that report, so high expectations. Their benefits expense ratio came in lower than expected (good), but the core insurance segment ratio's was higher than expected. Also, their forecast suggests this ratio could go higher, due to a wave of Covid cases that hit sooner than they expected. Wall St. didn't like that HUM did not upgrade their full-year guidance. HUM projected slower, but more profitable growth. Run by good managers. Own for the long term.

$488.910

Stock price when the opinion was issued

medical services
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

BUY
Caller works at a health facility where UNH is rejecting claims from a significant number of patients

That news is distressing. That's unfair. He switched to Humana for coverage, but also bought Humana shares.

BUY
Upgraded today

He just bought it. Profitable healthcare is a good place to be this year; it's very defensive

BUY ON WEAKNESS

He added on today's sell-off, which is an overreaction to HUM reiterating weak guidance. The company has a strong record of performance.

BUY

Humana has gone from $420 to $500 in the past month. Healthcare stocks are climbing, but he prefers HC insurance than the drug companies, because their earnings are more predictable and trade a lot cheaper. 42% of Americans are obesity, so there's a lot of potential demand for these new, popular diet drugs. However, a lot of these people are also insured. Remember that the drugs space is competitive and eventually new drugs go generic. Insurance doesn't suffer that problem, and there isn't much variability in their earnings (they're more predictable). He also likes UNH.

BUY

Cheaper than UHN which he strongly likes, and shares the same fundamenentals.

PAST TOP PICK
(A Top Pick Feb 01/23, Up 1%)

It's been a choppy year for US health insurers, limited by an uptick in elective surgeries. But this is temporary. Human remains dominant in this sector and the population is aging. Should continue to compound. Happy to hold onto this.

COMMENT

The proposed merger with Cigna is a terrible idea. Humana was doing well, so why do they need Cigna? The FTC will resist this merger and the FTC will be right.

DON'T BUY

Affected by upcoming US election concerns. Investors worried new government will limit profits on US drug companies. Generally speaking, better names for investors in healthcare sector. Does not own shares. 

SELL

He was lucky to get out of this before today's 11% slide. If you can't price your products, get out of the business.